Apogee Therapeutics Inc. (NASDAQ:APGE) Shares Bought by Victory Capital Management Inc.

Victory Capital Management Inc. boosted its stake in Apogee Therapeutics Inc. (NASDAQ:APGE - Free Report) by 4.4% in the first quarter, according to the company in its most recent disclosure with the Securities and Exchange Commission (SEC). The fund owned 232,983 shares of the company's stock after acquiring an additional 9,921 shares during the period. Victory Capital Management Inc. owned about 0.52% of Apogee Therapeutics worth $8,704,000 as of its most recent SEC filing.

Other institutional investors and hedge funds have also recently bought and sold shares of the company. GF Fund Management CO. LTD. purchased a new stake in Apogee Therapeutics in the fourth quarter valued at $43,000. Optimize Financial Inc purchased a new stake in shares of Apogee Therapeutics in the fourth quarter valued at about $203,000. BNP Paribas Financial Markets purchased a new stake in shares of Apogee Therapeutics in the fourth quarter valued at about $219,000. Commonwealth Equity Services LLC purchased a new stake in shares of Apogee Therapeutics in the fourth quarter valued at about $222,000. Finally, KLP Kapitalforvaltning AS purchased a new stake in shares of Apogee Therapeutics in the fourth quarter valued at about $226,000. 79.04% of the stock is owned by hedge funds and other institutional investors.

Apogee Therapeutics Stock Down 0.6%

NASDAQ APGE traded down $0.26 during trading hours on Monday, hitting $40.56. 89,502 shares of the stock were exchanged, compared to its average volume of 760,028. The company has a market cap of $1.87 billion, a price-to-earnings ratio of -11.27 and a beta of 1.47. Apogee Therapeutics Inc. has a 12-month low of $26.20 and a 12-month high of $63.50. The stock has a 50-day moving average of $40.43 and a 200 day moving average of $38.13.

Apogee Therapeutics (NASDAQ:APGE - Get Free Report) last issued its earnings results on Monday, May 12th. The company reported ($0.95) earnings per share for the quarter, topping the consensus estimate of ($1.19) by $0.24. On average, equities research analysts expect that Apogee Therapeutics Inc. will post -3.09 earnings per share for the current year.

Insiders Place Their Bets

In other Apogee Therapeutics news, insider Carl Dambkowski sold 10,090 shares of the company's stock in a transaction dated Wednesday, July 2nd. The shares were sold at an average price of $45.09, for a total transaction of $454,958.10. Following the transaction, the insider directly owned 238,998 shares in the company, valued at approximately $10,776,419.82. This represents a 4.05% decrease in their ownership of the stock. The sale was disclosed in a filing with the SEC, which can be accessed through this link. Insiders have sold 15,540 shares of company stock worth $653,093 in the last quarter. Corporate insiders own 42.77% of the company's stock.

Wall Street Analyst Weigh In

APGE has been the subject of a number of research reports. Guggenheim reaffirmed a "buy" rating and issued a $116.00 target price on shares of Apogee Therapeutics in a report on Wednesday, July 2nd. BTIG Research increased their price target on shares of Apogee Therapeutics from $100.00 to $115.00 and gave the stock a "buy" rating in a report on Monday, July 7th. Citigroup reissued a "buy" rating on shares of Apogee Therapeutics in a report on Monday, July 7th. Finally, Wedbush reissued an "outperform" rating and set a $90.00 price target on shares of Apogee Therapeutics in a report on Monday, July 7th. Six equities research analysts have rated the stock with a buy rating, According to MarketBeat.com, the company presently has an average rating of "Buy" and a consensus target price of $99.00.

Apogee Therapeutics Profile

Apogee Therapeutics, Inc, through its subsidiary, operates as a biotechnology company that develops biologics for the treatment of atopic dermatitis (AD), asthma, chronic obstructive pulmonary disease (COPD), and related inflammatory and immunology indications. The company primarily develops APG777, a subcutaneous (SQ) extended half-life monoclonal antibody (mAb) for AD; and APG808, an SQ extended half-life mAb for COPD.